ArticleDrug metabolism and disposition: the biological fate of chemicals2021
Open access · hybridAbstract read
In one paragraph
Article in Drug metabolism and disposition: the biological fate of chemicals, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Overcoming extrapolation challenges of deep learning by incorporating physics in protein sequence-function modeling.PLoS computational biology · 2026Article
- Overcoming Extrapolation Challenges of Deep Learning by Incorporating Physics in Protein Sequence-Function Modeling.bioRxiv : the preprint server for biology · 2025Article
- Translating pharmacogenomic sequencing data into drug response predictions-How to interpret variants of unknown significance.British journal of clinical pharmacology · 2025Review
- The full spectrum of SLC22 OCT1 mutations illuminates the bridge between drug transporter biophysics and pharmacogenomics.Molecular cell · 2024Article
- Article
- ACIDES: on-line monitoring of forward genetic screens for protein engineering.Nature communications · 2023Article
- Interstitial Lung Disease in Adulthood Associated with Surfactant Protein C Gene Mutation in a Patient with a History of Lipoid Pneumonia in Infancy.Internal medicine (Tokyo, Japan) · 2023Article
- The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.bioRxiv : the preprint server for biology · 2023Article
- The landscape of tolerated genetic variation in humans and primates.bioRxiv : the preprint server for biology · 2023Article
- ACE2 and TMPRSS2 SARS-CoV-2 infectivity genes: deep mutational scanning and characterization of missense variants.Human molecular genetics · 2022Article
- Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for Carnitine Transporter Deficiency.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- New and Emerging Research on Solute Carrier and ATP Binding Cassette Transporters in Drug Discovery and Development: Outlook From the International Transporter Consortium.Clinical pharmacology and therapeutics · 2022Review
- Keeping pace withPharmacogenomics · 2022Review
- Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing?The Journal of molecular diagnostics : JMD · 2022Article
- Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants:Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Lingxin ZhangDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (L.Z., M.-F.H., I.M., L.W., R.M.W.), Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (V.S., K.R.K.), and Mayo Clinic Center for Individualized Medicine (L.W., R.M.W.), Mayo Clinic, Rochester, Minnesota.
Vivekananda SarangiDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (L.Z., M.-F.H., I.M., L.W., R.M.W.), Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (V.S., K.R.K.), and Mayo Clinic Center for Individualized Medicine (L.W., R.M.W.), Mayo Clinic, Rochester, Minnesota.
Ming-Fen HoDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (L.Z., M.-F.H., I.M., L.W., R.M.W.), Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (V.S., K.R.K.), and Mayo Clinic Center for Individualized Medicine (L.W., R.M.W.), Mayo Clinic, Rochester, Minnesota.
Irene MoonDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (L.Z., M.-F.H., I.M., L.W., R.M.W.), Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (V.S., K.R.K.), and Mayo Clinic Center for Individualized Medicine (L.W., R.M.W.), Mayo Clinic, Rochester, Minnesota.
Krishna R KalariDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (L.Z., M.-F.H., I.M., L.W., R.M.W.), Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (V.S., K.R.K.), and Mayo Clinic Center for Individualized Medicine (L.W., R.M.W.), Mayo Clinic, Rochester, Minnesota.
Liewei WangDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (L.Z., M.-F.H., I.M., L.W., R.M.W.), Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (V.S., K.R.K.), and Mayo Clinic Center for Individualized Medicine (L.W., R.M.W.), Mayo Clinic, Rochester, Minnesota weinshilboum.richard@mayo.edu Wang.Liewei@mayo.edu.
Richard M WeinshilboumDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (L.Z., M.-F.H., I.M., L.W., R.M.W.), Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (V.S., K.R.K.), and Mayo Clinic Center for Individualized Medicine (L.W., R.M.W.), Mayo Clinic, Rochester, Minnesota weinshilboum.richard@mayo.edu Wang.Liewei@mayo.edu.
Mayo Clinic · US
Funding
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8MINHERITED VARIATIONS IN DRUG-METABOLIZING ENZYMESR01GM028157 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 1985 to 2019
$6.9MAlcohol Use Disorder: Acamprosate Pharmacometabolomics-informed PharmacogenomicsR01AA027486 · NIAAA · MAYO CLINIC ROCHESTER · PI Ming-Fen Ho, Richard M. Weinshilboum · 2018 to 2026
$4.0MPharmacogenomic regulation of CYP transcription by TSPYL genesR01GM125633 · NIGMS · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2018 to 2021
$1.2MAcamprosate pharmacogenomics: iPSC based model of alcohol use disorderK01AA028050 · NIAAA · MAYO CLINIC ROCHESTER · PI HO, MING-FEN · 2019 to 2024
$649kNIAAA NIH HHS K01 AA028050NIAAA NIH HHS R01 AA027486NIGMS NIH HHS R01 GM028157NIGMS NIH HHS R01 GM125633NIGMS NIH HHS U19 GM061388
Abstract
PubMed holds no abstract for this paper.
Indexed as
Genetic VariationGenomicsHEK293 CellsHumansLiver-Specific Organic Anion Transporter 1Mutation, MissenseLiver-Specific Organic Anion Transporter 1SLCO1B1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.